By characterizing the unique features of both AP‐1‐expressing, core‐associated CLL cells and the novel, core‐associated BMSC subset, our data offer promising approaches for the development of therapeutic strategies that disrupt these critical interactions in CLL. The gene discussed is FOS; the disease is B-cell chronic lymphocytic leukemia.